De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Greenwich LifeSciences Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Snehal Patel
Algemeen directeur
US$2.8m
Totale compensatie
| Percentage CEO-salaris | 20.2% |
| Dienstverband CEO | 14.7yrs |
| Eigendom CEO | 42.1% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 14.7yrs |
Recente managementupdates
Recent updates
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Aug 22
Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge
Jun 26Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$3m | US$557k | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$2m | US$506k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$6m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$1m | US$450k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$2m |
| Dec 31 2020 | US$999k | US$115k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$1m |
| Jun 30 2020 | n/a | n/a | -US$1m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$139k | n/a | -US$3m |
Compensatie versus markt: De totale vergoeding ($USD 2.75M ) Snehal } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).
Compensatie versus inkomsten: De vergoeding van Snehal is gestegen terwijl het bedrijf verliesgevend is.
CEO
Snehal Patel (60 yo)
14.7yrs
Tenure
US$2,750,029
Compensatie
Mr. Snehal S. Patel has been Chief Executive Officer of Greenwich Lifesciences Inc. since June 2016 and has been Chief Financial Officer and Director since February 2010. He serves as Managing Director at...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, CFO & Director | 14.7yrs | US$2.75m | 42.12% $ 76.1m | |
| Founder & Independent Director | 18.2yrs | US$65.64k | 2.38% $ 4.3m | |
| Chief Medical Officer & Director | 5.1yrs | geen gegevens | 0.69% $ 1.2m | |
| Independent Chairman of the Board | 15.7yrs | US$98.39k | 4.72% $ 8.5m | |
| Independent Director | 5.1yrs | US$65.64k | 3.02% $ 5.5m |
14.7yrs
Gemiddelde duur
73yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GLSI zijn ervaren en ervaren (gemiddelde ambtstermijn van 14.7 jaar).